News &
Media
-
Webinar Recap – NTI, MHK, RPM & ESK
View More -
Australia’s top 20 cannabis companies
View MoreA report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.
-
Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO
View MoreDr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.
-
Neurotech International Phase I/II Autism Results Due this Quarter
View MoreIn July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.
-
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
View More -
From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream
View MoreExplore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.
-
Australia’s Neurotech Inks Cannabis Cultivation Partnership
View MoreNeurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.
-
Neurotech just started world’s first THC-less cannabis study in autistic children
View MoreThe Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.
-
Neurotech embarks on ground-breaking ASD trials
View MoreNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).